drugset / Trial / NCT00062647
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
Timeline
- Start
- 2003-08
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telavancin | Other / unclassified | 10 mg/kg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | 1 g | Intravenous |
| Comparator | cloxacillin | Other / unclassified | 2 g | Intravenous |
| Comparator | nafcillin | Small molecule | 2 g | Intravenous |
| Comparator | oxacillin | Small molecule | 2 g | Intravenous |